Caroline Palomeque
Stock Analyst at Ladenburg Thalmann & Co.
(0.10)
# 4,838
Out of 5,162 analysts
159
Total ratings
30.2%
Success rate
-11.8%
Average return
Main Sectors:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $54 → $55 | $33.11 | +66.11% | 3 | Oct 15, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $16 | $3.12 | +412.82% | 2 | Aug 10, 2026 | |
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $10 | $1.70 | +488.24% | 1 | Jun 16, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $154 | $315.34 | n/a | 2 | Oct 25, 2023 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $58 | $95.80 | n/a | 7 | Sep 11, 2023 | |
| ASND Ascendis Pharma | Reiterated: Buy | $166 | $270.33 | n/a | 12 | Sep 7, 2023 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $33 | $8.12 | n/a | 7 | Aug 16, 2023 | |
| AVXL Anavex Life Sciences | Reiterated: Buy | $40 | $0.7194 | n/a | 24 | Aug 9, 2023 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $54 | $18.40 | n/a | 14 | Aug 9, 2023 | |
| OCUL Ocular Therapeutix | Reiterated: Buy | $15 | $5.94 | n/a | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $7.26 | n/a | 12 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $6.70 | n/a | 2 | Apr 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $3.36 | n/a | 5 | Apr 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.45 | n/a | 8 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.71 | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.1995 | n/a | 14 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $0.899 | n/a | 13 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 1,332p → 1,362p | 527p | n/a | 2 | Mar 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $0.273 | n/a | 3 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $2.75 | n/a | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.81 | n/a | 6 | Mar 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 | $7.30 | n/a | 1 | Aug 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.000001 | n/a | 1 | Jun 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.0002 | n/a | 1 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.8248 | n/a | 1 | May 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.091 | n/a | 1 | Apr 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.0005 | n/a | 1 | Mar 2, 2016 |
Harmony Biosciences Holdings
Oct 15, 2026
Initiated Coverage: Buy
Price Target: $54 → $55
Current: $33.11
Upside: +66.11%
Ardelyx
Aug 10, 2026
Reiterated: Buy
Price Target: $16
Current: $3.12
Upside: +412.82%
Alterity Therapeutics
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Krystal Biotech
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $154
Current: $315.34
Upside: n/a
Halozyme Therapeutics
Sep 11, 2023
Reiterated: Buy
Price Target: $58
Current: $95.80
Upside: n/a
Ascendis Pharma
Sep 7, 2023
Reiterated: Buy
Price Target: $166
Current: $270.33
Upside: n/a
COMPASS Pathways
Aug 16, 2023
Reiterated: Buy
Price Target: $33
Current: $8.12
Upside: n/a
Anavex Life Sciences
Aug 9, 2023
Reiterated: Buy
Price Target: $40
Current: $0.7194
Upside: n/a
Denali Therapeutics
Aug 9, 2023
Reiterated: Buy
Price Target: $54
Current: $18.40
Upside: n/a
Ocular Therapeutix
Aug 8, 2023
Reiterated: Buy
Price Target: $15
Current: $5.94
Upside: n/a
Aug 3, 2023
Reiterated: Buy
Price Target: $61
Current: $7.26
Upside: n/a
Apr 29, 2019
Reiterated: Buy
Price Target: $10
Current: $6.70
Upside: n/a
Apr 23, 2019
Rated: Buy
Price Target: $5
Current: $3.36
Upside: n/a
Apr 4, 2019
Reiterated: Buy
Price Target: $3
Current: $0.45
Upside: n/a
Apr 1, 2019
Downgraded: Hold
Price Target: n/a
Current: $1.71
Upside: n/a
Apr 1, 2019
Reiterated: Buy
Price Target: $6
Current: $0.1995
Upside: n/a
Mar 28, 2019
Reiterated: Buy
Price Target: $9
Current: $0.899
Upside: n/a
Mar 14, 2019
Reiterated: Buy
Price Target: 1,332p → 1,362p
Current: 527p
Upside: n/a
Mar 20, 2018
Rated: Buy
Price Target: $34
Current: $0.273
Upside: n/a
Mar 13, 2018
Rated: Buy
Price Target: $20
Current: $2.75
Upside: n/a
Mar 9, 2018
Rated: Buy
Price Target: $9
Current: $1.81
Upside: n/a
Aug 8, 2017
Rated: Buy
Price Target: $8
Current: $7.30
Upside: n/a
Jun 13, 2017
Rated: Buy
Price Target: n/a
Current: $0.000001
Upside: n/a
Jun 7, 2017
Rated: Buy
Price Target: n/a
Current: $0.0002
Upside: n/a
May 17, 2017
Rated: Buy
Price Target: n/a
Current: $0.8248
Upside: n/a
Apr 24, 2017
Rated: Buy
Price Target: n/a
Current: $0.091
Upside: n/a
Mar 2, 2016
Initiated Coverage: Buy
Price Target: $18
Current: $0.0005
Upside: n/a